Validation of Toxicogenomics-Based Test Systems
Author Information
Author(s): Raffaella Corvi, Hans-Jürgen Ahr, Silvio Albertini, David H. Blakey, Libero Clerici, Sandra Coecke, George R. Douglas, Laura Gribaldo, John P. Groten, Bernd Haase, Karen Hamernik, Thomas Hartung, Tohru Inoue, Ian Indans, Daniela Maurici, George Orphanides, Diana Rembges, Susanna-Assunta Sansone, Jason R. Snape, Eisaku Toda, Weida Tong, Joost H. van Delft, Brenda Weis, Leonard M. Schechtman
Primary Institution: European Centre for the Validation of Alternative Methods (ECVAM)
Hypothesis
What are the principles applicable to the validation of toxicogenomics platforms and specific toxicologic test methods?
Conclusion
The workshop identified key validation principles and recommendations for the future use of toxicogenomics in regulatory decision-making.
Supporting Evidence
- Toxicogenomics can help identify biological activity of chemicals and drugs.
- Validation of toxicogenomics methods is essential for regulatory acceptance.
- Early identification of biomarkers can improve safety assessments.
- Standardization of methods is necessary to ensure reliability.
- Collaboration among scientists, regulators, and industry is crucial for progress.
Takeaway
Scientists are figuring out how to use new gene testing methods to make sure they work well and can be trusted for safety assessments.
Methodology
The workshop involved discussions among experts on the validation of toxicogenomics methods and their regulatory implications.
Limitations
The rapid evolution of technology may complicate the validation process.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website